主页 > 医药科学 >
【medical-news】2008年国际Alzheimer疾病大会消息：血
Angiotensin-Receptor Blockers Associated With Reduced Incidence of Dementia and Progression to Dementia: Presented at ICAD
By Ed Susman
CHICAGO -- July 28, 2008 -- Patients who are taking angiotensin-receptor blockers (ARBs) for treatment of high blood pressure appear to have a reduced progression to Alzheimer's disease and other dementias, even when compared with patients taking angiotensin-converting enzyme (ACE) inhibitors, researchers said here at the 2008 International Conference on Alzheimer's Disease (ICAD).
"Angiotensin-receptor blockers appear to be neuroprotective," said Benjamin Wolozin, MD, Boston University School of Medicine, Boston, Massachusetts.
Dr. Wolozin and colleagues reviewed data from the United States' Veterans Affairs database from 2002 to 2006, identifying patients aged >65 years who were treated with ARBs, the ACE inhibitor lisinopril, and other cardiovascular medications. The 3 groups of patients were then compared with one another regarding development of dementia and then progression of dementia as defined by prescriptions for new neuroleptic drugs, transfer of the patient to a nursing home, or death.
"We found that use of angiotensin-receptor blockers is associated with a significant reduction in the incidence and progression of Alzheimer's disease, or dementia generally, compared with either users of ACE inhibitors or other cardiovascular medications," Dr. Wolozin said in an oral presentation on July 27.
The study included 185,906 patients who were taking 1 of 5 different angiotensin-receptor blockers (candesartan, irbesartan, telmisartan, losartan, and valsartan), 804,702 patients who were prescribed lisinopril, and 1,715,438 patients who were taking other cardiovascular medications. The subjects were about 74 years old, and about 98% were men.
After 4 years of follow-up, 1% of the patients on ARBs were diagnosed with Alzheimer's disease and 4% were diagnosed with dementia; 1.5% of those taking the ACE inhibitor or other cardiovascular medications were diagnosed with Alzheimer's disease, and 5% were diagnosed with dementia. Although the percentages are small, Dr. Wolozin said the large number of subjects in the study provided the statistical power to make those differences statistically significant (P < .0001).
He said that taking ARBs decreased the risk of developing dementia by 20% compared with lisinopril and by 33% compared with the other cardiovascular medications.
Similarly, the progression of disease was higher among those subjects taking the ACE inhibitors or other cardiovascular medications. Patients on ARBs had a lower risk of requiring new neuroleptic drugs by 23% (P < .05) compared with general cardiovascular treatment and by 14% compared with lisinopril (P = NS). They reduced their odds of having to be placed in a nursing home by 53% compared with cardiovascular drugs
(P < .0001) and by 38% compared with lisinopril (P < .05). Their odds of death were reduced by 36% when compared with those on other cardiovascular drugs (P < .0001) and by 23% (P < .05) compared with patients taking lisinopril.
"It would not be responsible to make any recommendations for treatment based on this study," Dr. Wolozin said. "We need to replicate the results of this retrospective study with other large databases of patients, and such a study is being performed by researchers at Kaiser Permanente of Northern California."
He said that if the Kaiser study replicates his results, then a prospective study would be warranted.
http://www.docguide.com/news/content.nsf/news/852571020057CCF68525749400582521 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Angiotensin-Receptor Blockers Associated With Reduced Incidence of Dementia and Progression to Dementia: Presented at ICAD
By Ed Susman
国际阿尔兹海默病会议（ICAD）报道：血管紧张素受体阻滞剂可降低痴呆发病率并延缓其发病进程
CHICAGO -- July 28, 2008 -- Patients who are taking angiotensin-receptor blockers (ARBs) for treatment of high blood pressure appear to have a reduced progression to Alzheimer's disease and other dementias, even when compared with patients taking angiotensin-converting enzyme (ACE) inhibitors, researchers said here at the 2008 International Conference on Alzheimer's Disease (ICAD).
芝加哥（2008.07.28 — 研究者在2008年国际阿尔兹海默病会议上报道，服用血管紧张素受体阻滞剂治疗高血压得患者发展为阿尔兹海默病或其他痴呆的进程得到了延缓。该差别甚至存在于这些患者与服用血管紧张素转化酶抑制剂的患者之间。
"Angiotensin-receptor blockers appear to be neuroprotective," said Benjamin Wolozin, MD, Boston University School of Medicine, Boston, Massachusetts.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-06-22 17:21
医学,生命科学网